BLUE, Bluebird Bio, has developed a new drug up for consideration for FDA approval.
A gene therapy for transfusion-dependent β-thalassemia, a Middle Eastern genetic blood disease. This drug might actually work. But most importantly for a gene therapy, no patients in their (small) study died!
My doctor friend thinks it will get recommended at the FDA committee meeting. ( I forgot when that is. Not too soon. I'll update when I can.)
The stock is around $3 today. This company has horrible financials. It lost more than 75% of its value in the last year and it’s been dropping since its high of $150 in 2019.
If this drug gets recommended by the FDA committee, likely the stock will rise. Best case is that it will then be bought out by a more viable drug development company.